Vaccines of the invention include at least four influenza virus strains. In someembodiments, the vaccines are produced in cell culture rather than in eggs. Insome embodiments, the vaccines include an adjuvant. In some embodiments, thevaccines are not split or whole virion vaccines, but are live or purified glycoproteinvaccines. In some embodiments, the vaccines contain substantially the samemass of hemagglutinin (HA) for each of the influenza virus strains. In some embodiments,the four strains will include two influenza A virus strains and two influenzaB virus strains ('A-A-B-B'). In other embodiments, the four strainswill include three influenza A virus strains and one influenza B virus strain('A-A-A-B').
